<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03479671</url>
  </required_header>
  <id_info>
    <org_study_id>831425</org_study_id>
    <nct_id>NCT03479671</nct_id>
  </id_info>
  <brief_title>Low Dose Fat-Induced Insulin Resistance</brief_title>
  <acronym>BCAA</acronym>
  <official_title>A Dose Finding Study for Fat-Induced Insulin Resistance in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Pennsylvania</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary goal of this study is to determine the dose of fatty acids that acutely induces&#xD;
      mild insulin resistance in healthy volunteers. We hypothesize that a low-dose of fatty acid&#xD;
      infusion (Intralipid/heparin) will cause a mild insulin resistance. The dose of fatty acid&#xD;
      infusion that reliably causes mild insulin resistance will be selected for use in future&#xD;
      studies.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is designed to test the hypothesis that a low-dose of fatty acid infusion&#xD;
      (Intralipid/heparin) will cause mild insulin resistance. This dose-finding study is critical&#xD;
      for future studies on free-fatty acid induced insulin resistance.&#xD;
&#xD;
      Healthy male and healthy female volunteers will undergo a 6 hour hyperinsulinemic-euglycemic&#xD;
      clamp, in order to establish insulin sensitivity parameters in the presence of fatty acid&#xD;
      co-infusion. The subjects will then return 1-3 weeks later, and undergo another 6 hour HIE&#xD;
      clamp, this time in the presence of low-dose fatty acid co-infusion (30ml/hr). If this dose&#xD;
      does not achieve ~25% reduction in the rate of glucose disposal, then the dose-confirmation&#xD;
      study will be repeated 1-3 weeks later with a medium-dose fatty acid co-infusion (60ml/hr).&#xD;
&#xD;
      A dose-response effect of fatty acids on insulin resistance has been demonstrated before, but&#xD;
      not in the precise conditions of our study. This dose-finding study is critical because&#xD;
      future studies require a reliable dose of fatty acid infusion, and the exact dose of fatty&#xD;
      acid infusion that causes mild insulin resistance may be different in the conditions of our&#xD;
      study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2020</start_date>
  <completion_date type="Anticipated">January 2026</completion_date>
  <primary_completion_date type="Anticipated">January 2025</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Baseline insulin sensitivity will be measured in healthy volunteers, and then 1-3 weeks later insulin sensitivity will be measured in response to a low-dose fatty acid infusion. If there is no response to this low-dose infusion, then 1-3 weeks later insulin sensitivity will be measured in response to a medium-dose fatty acid infusion.</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Insulin Sensitivity</measure>
    <time_frame>6 hours</time_frame>
    <description>Rate of Glucose Disposal (mg/kg/min)</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <condition>Insulin Resistance</condition>
  <condition>Insulin Sensitivity</condition>
  <arm_group>
    <arm_group_label>Saline</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Insulin sensitivity (rate of glucose disposal)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low Dose Fatty Acids</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Insulin sensitivity (rate of glucose disposal) in response to 30 ml/hr fatty acid infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Medium Dose Fatty Acids</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Insulin sensitivity (rate of glucose disposal) in response to 60 ml/hr fatty acid infusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intralipid, 20% Intravenous Emulsion</intervention_name>
    <description>Fatty Acid Infusion, either in low-dose (30 ml/hr) or medium-dose (60 ml/hr)</description>
    <arm_group_label>Low Dose Fatty Acids</arm_group_label>
    <arm_group_label>Medium Dose Fatty Acids</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects who are able to provide written informed consent and to comply with the&#xD;
             procedures of the study protocol&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of diabetes&#xD;
&#xD;
          -  History of diabetes in more than one first-degree relative&#xD;
&#xD;
          -  Body mass index (BMI) &lt;19 or &gt;27 kg/m2&#xD;
&#xD;
          -  HbA1c &gt;5.7%&#xD;
&#xD;
          -  Blood Pressure: systolic &gt;160 mmHg or diastolic &gt; 100 mmHg&#xD;
&#xD;
          -  Baseline hemoglobin concentration &lt; 11 g/dl in women and &lt; 12 g/dl in men&#xD;
&#xD;
          -  Estimated glomerular filtration rate &lt; 55 ml/min/1.73 m2 (calculated using the&#xD;
             subject's measured serum creatinine and the Modification of Diet in Renal Disease&#xD;
             [MDRD] study estimation formula).&#xD;
&#xD;
          -  Presence of soy or egg allergies (due to possible reactions with fat infusate)&#xD;
&#xD;
          -  For female participants: Positive pregnancy test, presently breast-feeding, or&#xD;
             unwillingness to use effective contraceptive measures for the duration of the study.&#xD;
             Oral contraceptives, Norplant®, Depo-Provera®, and barrier devices with spermicide are&#xD;
             acceptable contraceptive methods; condoms used alone are not acceptable.&#xD;
&#xD;
          -  Known active alcohol or substance abuse&#xD;
&#xD;
          -  Use of tobacco within the previous year&#xD;
&#xD;
          -  Severe co-existing cardiac disease, characterized by any one of these conditions:&#xD;
&#xD;
               1. history of myocardial infarction within past 6 months;&#xD;
&#xD;
               2. history of ischemia on functional cardiac exam within the last year;&#xD;
&#xD;
               3. history of left ventricular ejection fraction &lt; 30%.&#xD;
&#xD;
          -  Persistent elevation of liver function tests &gt; 1.5 times normal upper limits&#xD;
&#xD;
          -  Hyperlipidemia (fasting LDL cholesterol &gt; 130 mg/dl, treated or untreated; and/or&#xD;
             fasting triglycerides &gt; 200 mg/dl)&#xD;
&#xD;
          -  Receiving treatment for a medical condition requiring chronic use of systemic&#xD;
             steroids, except for the use of ≤ 5 mg prednisone daily, or an equivalent&#xD;
             physiological dose of hydrocortisone&#xD;
&#xD;
          -  Presence of a seizure disorder&#xD;
&#xD;
          -  Use of any investigational agents within 4 weeks of enrollment&#xD;
&#xD;
          -  Any medical condition, which in the opinion of the investigator, will interfere with&#xD;
             the safe completion of the study&#xD;
&#xD;
          -  History of pancreatitis&#xD;
&#xD;
          -  Presence of a metal allergy (aluminum)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Male or Female at birth.</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>39 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zoltan P Arany, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Associate Professor of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Paola Alvarado, BS</last_name>
    <phone>215-746-2081</phone>
    <email>Paola.Alvarado@Pennmedicine.upenn.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Michael D Neinast, BS</last_name>
    <phone>469-323-7470</phone>
    <email>mneinast@pennmedicine.upenn.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paola Alvarado, B.S.</last_name>
      <phone>215-746-2081</phone>
      <email>Paola.Alvarado@Pennmedicine.upenn.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>March 20, 2018</study_first_submitted>
  <study_first_submitted_qc>March 20, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 27, 2018</study_first_posted>
  <last_update_submitted>August 31, 2021</last_update_submitted>
  <last_update_submitted_qc>August 31, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Pennsylvania</investigator_affiliation>
    <investigator_full_name>Zoltan Arany</investigator_full_name>
    <investigator_title>Associate Professor Of Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Insulin Resistance</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Soybean oil, phospholipid emulsion</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

